Open Drug Discovery Center for Alzheimer's Disease

AD开放药物发现中心(Open-AD)管理和数据管理核心(管理和 数据核心)服务于三个职能：(1)提供全面的行政组织、监督和管理 对于在Open-AD内执行的所有工作，(2)管理与外部AD调查人员的沟通 社区包括确定目标优先级，以及(3)支持开放分发所有生成的Open-AD 供独立调查人员使用的试剂、工具、探针、数据和知识。管理和数据核心 将建立和实施行政和管理结构，以确保中心适当 满足里程碑和交付成果，正在征求意见并在社区内公开共享资产，并且是 跨核心工作，以便在目标计划通过时对其进行有效评估和管理 中央管道。此外，管理核心将管理Open-AD与外部研究的交互 社区，以便在不同的投资组合中征求和评估社区优先的一组目标 治疗假说，以确定可以作为指导决策的顾问和合作伙伴的领域专家 围绕每个选定的治疗性假设，并确定将使用这些资产的研究人员 由该中心开发，用于测试这些(和其他)治疗假说。与外部研究的互动 社区将通过开放AD专家小组、外部咨询委员会、每年一次的 开放AD会议、特定目标研讨会以及通过Agora平台(以前称为AMP-AD墙 目标，agora.ampadportal.org)。为了邀请整个AD研究社区参与我们的 调查新的目标，拟议的开放AD中心将采用一种彻底开放的方法来实现目标 验证和药物发现。所有Open-AD调查人员已同意将所有数据、知识、试剂 以及包括化学和生物探测器在内的工具进入开放领域，没有知识产权主张。至 支持广泛分发并鼓励重复使用，Open-AD将捐赠任何试剂的分发权给 商业供应商，非排他性和无偿。中心的所有活动将在 使用Open-AD协作工作区打开。为每个项目开发的所有资源、数据和知识 治疗方法将使用标准资源(用于cDNA克隆的Addgene，Thermo Fisher)进行传播 对于抗体等)-所有信息将通过Agora平台汇总和注册。

The Open Drug Discovery Center for AD (Open-AD) Administrative and Data Management Core (Admin and Data Core) serves three functions: (1) to provide overall administrative organization, oversight and management for all work performed within the Open-AD, (2) to manage communications with external AD investigators across the community including for target prioritization, and (3) to support the open distribution of all Open-AD generated reagents, tools, probes, data, and knowledge for use by independent investigators. The Admin and Data Core will establish and implement administrative and management structures to ensure that the Center is appropriately meeting milestones and deliverables, is soliciting input and openly sharing assets across the community, and is working across Cores for effective evaluation and management of target programs as they move through the Center pipeline. In addition, the Admin Core will manage Open-AD interactions with the external research community so as to solicit and evaluate a community-prioritized set of targets across a diverse portfolio of therapeutic hypotheses, to identify domain experts that can serve as advisors and partners to guide decisions around each therapeutic hypothesis that is selected, and to identify researchers that will use the assets developed by the Center to test these (and other) therapeutic hypotheses. Interactions with the external research community will be performed through the Open-AD AD expert panel, the External Advisory Board, an annual Open-AD meeting, target-specific workshops, and through the Agora platform (formerly called the AMP-AD Wall of Targets, agora.ampadportal.org). In order to invite the entire AD research community to participate in our investigation of novel targets, the proposed Open-AD Center will adopt a radically open approach to target validation and drug discovery. All Open-AD investigators have agreed to place all data, knowledge, reagents, and tools including chemical and biological probes into the open domain with no intellectual property claims. To support wide distribution and encourage reuse, Open-AD will donate the rights to distribute any reagent to commercial suppliers, non-exclusively and for no compensation. All Center activities will be performed in the open using the Open-AD collaboration workspace. All resources, data, and knowledge developed for each therapeutic approach will be disseminated using standard resource (AddGene for cDNA clones, Thermo Fisher for antibodies, etc) – and all information will be summarized and registered through the Agora platform.